SCHEMBL13293264

SCHEMBL13293264

C=C(CO)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC/C(=N/O)C(C)(CC)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 10/20 0.60
▸ EGLN2 Q96KS0 1/20 0.59
▸ EGLN1 Q9GZT9 1/20 0.59
▸ EGLN3 Q9H6Z9 1/20 0.59
▸ P4HTM Q9NXG6 1/20 0.59
▸ LMNA P02545 2/20 0.59
▸ NT5E P21589 2/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ CES2 O00748 2/20 0.56
▸ CES1 P23141 2/20 0.56
▸ F3 P13726 1/20 0.56
▸ PTPN1 P18031 2/20 0.54
▸ GLI1 P08151 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ AKR1B10 O60218 1/20 0.54
▸ ALB P02768 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ AKR1B1 P15121 1/20 0.54
▸ DPP4 P27487 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13304146 0.94 GPBAR1 (0.59) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL13293261 0.94 GPBAR1 (0.59) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL3507541 0.88 GPBAR1 (0.69) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL13293178 0.88 GPBAR1 (0.69) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL16704981 0.88 GPBAR1 (0.69) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL13293256 0.84 GPBAR1 (0.67) GPBAR1LMNANT5ESMN1; SMN2CES2
SCHEMBL13293163 0.83 EGLN2 (0.83) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL13910823 0.83 GPBAR1 (0.81) GPBAR1LMNANT5ESMN1; SMN2CES2
SCHEMBL14086933 0.83 EGLN2 (0.83) GPBAR1EGLN2EGLN1EGLN3P4HTM
SCHEMBL13293257 0.82 GPBAR1 (0.69) GPBAR1EGLN2EGLN1EGLN3P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144688-A1 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids ADVANCED LIFE SCIENCES, INC. (US) 2010-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144688-A1 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids BRCA1, PGF, LSS GPBAR1 465/4885EGLN2 1377/4885EGLN1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback